• Healthcare

  Important Safety Information on SUBOXONE (buprenorphine and naloxone)

  Posted by Nino on 9 January 2021 at 10:14 am

  Health Canada has authorized 2 dosage forms of SUBOXONE (buprenorphine and naloxone), a sublingual tablet and soluble film, that are not bioequivalent at all doses and routes of administration.

  Switching between dosage forms or routes of administration could result in variations in buprenorphine or naloxone blood plasma concentrations, which could lead to inadvertent overdosing or underdosing, including opioid withdrawal.

  Switching between SUBOXONE (buprenorphine and naloxone) Soluble Film and SUBOXONE Sublingual Tablet, or switching between different routes of administration using the film, could lead to inadvertent overdosing or underdosing. The film and tablet dosage forms are not bioequivalent at all doses and routes of administration.

  Why don’t Health Canada release this information mainstream so users themselves are able to access this important information, not just healthcare workers.

  

  Nino replied 3 years, 4 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply